Pfizer said Sunday its Braftovi-tied regimen nearly doubled the length of time colon cancer patients lived without getting sicker.
How S&P 500 Giant Pfizer Is Tackling Hard-To-Treat Cancers
Source: Investors Business Daily
More PFE News
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
Business Wire·5h ago
Mailbag: A Follow-Up on Pfizer & Other Questions
ETF Trends·1 day ago
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
GuruFocus·1 day ago
This Healthcare Stock With 6%-Plus Yield: Is the Dividend Safe?
The Motley Fool·5 days ago
The Most Important Healthcare Stock You're Not Watching
The Motley Fool·8 days ago